Tumor Treatment Response–Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma
International Journal of Radiation Oncology*Biology*Physics · 2026-03 · 124 (3) · 810-819
DOI: 10.1016/j.ijrobp.2025.09.049 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-03. Verfasst von Xiaoqiang Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy Physics and Technology Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Chemoradiotherapy, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Sichuan Provincial Science and Technology Support Program, West China Hospital, Sichuan University, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
PURPOSE: A novel tumor dose response-guided adaptive chemoradiation therapy process for nasopharyngeal carcinoma (NPC) was constructed and evaluated prospectively and retrospectively. In this process, tumor voxel dose response matrices (DRMs) quantified using 2-point fluorodeoxyglucose (FDG) positron emission tomography/magnetic resonance images acquired before and after an induction chemotherapy (IC) were used to guide quantitatively the individual patient dose de-escalation/escalation for patients with NPC in the post-IC concurrent chemoradiation therapy (CCRT). METHODS AND MATERIALS: Two fluorodeoxyglucose-positron emission tomography/magnetic resonance images were obtained before and after IC for each of 21 patients with stage III and IV NPC who underwent IC + CCRT. The changes of tumor voxel standardized uptake value (SUV0) on the pretreatment baseline image and the baseline voxel volume were tracked on the post-IC image using a deformable image registration tool and used to construct the tumor voxel DRM as the surrogate of tumor in situ SF2 at the voxel level. The equivalent dose in the IC treatment was determined, assuming that the IC treatment achieved the same mean DRM as the one achieved using a dose in the CCRT treatment alone. Therefore, the equivalent dose should not be extrapolated with respect to any other clinical endpoints. The tumor voxel SUV0 and DRM were used to predict the treatment outcome and retrospectively create the expected treatment dose for the post-IC CCRT treatment. For a few patients who were expected to receive a large dose escalation, new treatment plans targeting the highly resistant tumors were generated to assess the clinical feasibility of an adaptive dose fractionation painting schema. RESULTS: The equivalent dose in 2 Gy per fraction for 3 cycles IC (gemcitabine + cisplatin) was approximately 40 Gy. The mean and coefficient variation of SUV0 and DRM for all the primary tumors (gross tumor volume [GTV]-nasopharynx [GTVnx] group) were 5.98 (62%) and 0.42 (72%), respectively, which were significantly larger than 5.22 (59%) and 0.37 (55%) for the positive nodes (GTVnd) group, respectively (P 50% of the GTVs (GTVnx and GTVnd groups), meanwhile, escalated for about 16% of the GTVs with the local hypofractionation to the highly dose resistance regions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Radiotherapy Physics and Technology Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. Electronic address: rongtiannuclear@126.com.
- Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Electronic address: n_ychen@hotmail.com.
- Radiotherapy Physics and Technology Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Electronic address: dyanmay31@gmail.com.
Förderung
- Sichuan Provincial Science and Technology Support Program
- West China Hospital, Sichuan University
- Chinese Academy of Medical Sciences
- Sichuan University
Zitieren
APA
Chen, X., Zhang, S., Gou, X., Dai, J., Zeng, N., Duan, B., Shen, K., Wang, H., Zhong, R., Tian, R., Chen, N., & Yan, D. (2026). Tumor Treatment Response–Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics, 124(3), 810-819. https://doi.org/10.1016/j.ijrobp.2025.09.049
Vancouver
Chen X, Zhang S, Gou X, Dai J, Zeng N, Duan B, et al. Tumor Treatment Response–Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2026;124(3):810-819. doi:10.1016/j.ijrobp.2025.09.049
BibTeX
@article{Chen2026,
author = {Chen, Xiaoqiang and Zhang, Shu and Gou, Xiaofang and Dai, Jiaona and Zeng, Ni and Duan, Baofeng and Shen, Konglong and Wang, Hui and Zhong, Renming and Tian, Rong and Chen, Nianyong and Yan, Di},
title = {Tumor Treatment Response–Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {124},
number = {3},
pages = {810--819},
doi = {10.1016/j.ijrobp.2025.09.049}
}
EUVIMED